press releases

Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly… Read More

Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly… Read More

December 15, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017, in San Francisco. William Doyle, Novocure’s Executive Chairman,… Read More

December 15, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017, in San Francisco. William Doyle, Novocure’s Executive Chairman,… Read More

December 15, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017, in San Francisco. William Doyle, Novocure’s Executive Chairman,… Read More

Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine… Read More

Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine… Read More

Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine… Read More

Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer December 12, 2016 04:00 PM Eastern… Read More